FindTrial
Sign In

Multi-centre randomised double blind parallel group study: enalapril vs nifedipine vs placebo in diabetic patients

Multi-centre randomised double blind parallel group study: enalapril vs nifedipine vs placebo in diabetic patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN01207964
Enrollment
Unknown
Registered
2004-01-23
Start date
1993-01-04
Completion date
Unknown
Last updated
2019-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nutritional, metabolic and endocrine diseases: Diabetes Nutritional, Metabolic, Endocrine Diabetes

Interventions

Enalapril and nifedipine retard versus placebo

Sponsors

NHS R&D Regional Programme Register - Department of Health (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Diabetic patients with increased urinary albumin excretion

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

MeasureTime frame
Whether Enalapril (an ACE inhibitor) preferentially halts or reverses the progression of the glomerular lesions of diabetic nephropathy.—

Secondary

MeasureTime frame
Not provided at time of registration—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026